Chong Kun Dang Pharmaceutical Corp

185750.KS · Health Technology · Pharmaceuticals: Major · KR

ckdpharm.com

About

Chong Kun Dang Pharmaceutical Corp is one of the leading pharmaceutical companies in South Korea. It was founded in 1941 by Se-joong Oh in Seoul. The company initially produced a single medicine called "Kachetsan," which was a cough medicine made from natural herbs. The medicine was very successful and contributed to the company's growth. In 1969, the company was converted into a joint-stock company and expanded its portfolio of products. Chong Kun Dang Pharmaceutical Corp focuses on the research, development, manufacturing, and marketing of drugs. The company is divided into several divisions, each specializing in specific medicines. Chong Kun Dang produces its products based on sound scientific knowledge and innovative thinking. The company is committed to providing high-quality, safe, and effective medications to patients in South Korea and worldwide. The company has three main areas: pharmaceuticals, biotechnology, and over-the-counter (OTC) products. The pharmaceutical division includes medicines for infectious diseases, cancer, diabetes, and other ailments. Chong Kun Dang also has a pipeline of new medicines aimed at treating conditions such as liver fibrosis, obesity, chronic kidney disease, and eye diseases. One significant product in this division is the cancer drug called "Chong Kun Dang," used to treat bladder cancer. The biotechnology division focuses on developing biotechnological products, including antibodies, recombinant proteins, and enzymes. The division also has a research laboratory where new biotechnology products are developed and tested. The OTC products division produces products that can be sold without a prescription, such as pain relievers, cough and cold medications, vitamins, and dietary supplements. Chong Kun Dang Pharmaceutical Corp offers a variety of products sold under different brand names. One of the most well-known products is the stomach medicine "Acidezol." Another significant brand of the company is "Cymevene," an antiviral medication used to treat Herpes simplex infections. Other important products include "Glycalin," a blood sugar-lowering medication, "Pulmocare," an inhaler for asthma treatment, and "Tramadol," a painkiller. The company has received multiple awards for its products and efforts in developing new medications. It is based in Seoul and has branches in other parts of the world, including the United States and Europe. In summary, Chong Kun Dang Pharmaceutical Corp is a leading pharmaceutical company in South Korea specializing in the development, manufacturing, and marketing of medications. With three main divisions - pharmaceuticals, biotechnology, and OTC products - Chong Kun Dang produces a variety of high-quality, safe, and effective medications targeting patients in South Korea and worldwide. Through its innovative research and development, the company has made significant advancements in recent decades and is expected to continue playing a major role in the pharmaceutical industry in the future.

Annual results

Reported figures, KRW · revenue up 6.7% in 2025

YearRevenueNet incomeNet marginFree cash flow
20251.7T77.5B4.6%—
20241.6T109B6.9%—
20231.7T213B12.7%—
20221.5T81.0B5.4%—
20211.3T42.7B3.2%—

Dividends per share

2025 1600.00 KRW2024 1047.62 KRW2023 907.03 KRW2022 863.84 KRW2021 783.53 KRW

185750.KS in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Chong Kun Dang Pharmaceutical Corp are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Chong Kun Dang Pharmaceutical Corp (185750.KS) — company profile and financials · MarketPulse